Abstract:The chemokine receptors CCR5 and CXCR4 function as coreceptors for human immunodeficiency virus (HIV) and are attractive targets for the development of anti-HIV drugs. The most potent CXCR4 antagonists described until today are the bicyclams. The prototype compound, AMD3100, exhibits potent and selective anti-HIV activity against CXCR4-using (X4) viruses and showed antiviral efficacy in X4 HIV-1-infected persons in a phase II clinical trial. However, AMD3100 lacks oral bioavailability due to its high overall positive charge. Initial structure-activity relationship studies with bicyclam analogues suggested that the bis-macrocyclic structure was a prerequisite for anti-HIV activity. Now, we report that the N-pyridinylmethylene cyclam AMD3465, which lacks the structural constraints mentioned above, fully conserves all the biological properties of AMD3100. Like AMD3100, AMD3465 blocked the cell surface binding of both CXCL12 (the natural CXCR4 ligand), and the specific anti-CXCR4 monoclonal antibody 12G5. AMD3465 dose-dependently inhibited intracellular calcium signaling, chemotaxis, CXCR4 endocytosis and mitogen-activated protein kinase phosphorylation induced by CXCL12. Compared to the bicyclam AMD3100, AMD3465 was even 10-fold more effective as a CXCR4 antagonist, while showing no interaction whatsoever with CCR5. As expected, AMD3465 proved highly potent against X4 HIV strains (IC50: 1-10 nM), but completely failed to inhibit the replication of CCR5-using (R5) viruses. In conclusion, AMD3465 is a novel, monomacrocyclic anti-HIV agent that specifically blocks the interaction of HIV gp120 with CXCR4. Although oral bioavailability is not yet achieved, the monocyclams, with their decreased molecular charge as compared to the bicyclams, embody an important step forward in the design of oral CXCR4 antagonists that can be clinically used as anti-HIV drugs.

Selective synthesis of an elusive C-functionalized bis-cyclam through the bis-aminal route and study of its inhibition properties of CXCR4 chemokine receptor

Enantioselective Synthesis Of Axially Chiral Biaryls Via Cu-Catalyzed Acyloxylation Of Cyclic Diaryliodonium Salts

Trans-IV restriction: a new configuration for metal bis-cyclam complexes as potent CXCR4 inhibitors

Extending the scope of the C-functionalization of cyclam via Copper(I)-catalyzed Alkyne-Azide Cycloaddition to bifunctional chelators of interest

Selective 1,4-syn-Carboamination of Cyclic 1,3-Dienes via Hybrid Palladium Catalysis

Design, synthesis and biological evaluation of low molecular weight CXCR4 ligands

Extending the Scope of the C -Functionalization of Cyclam via Copper(I)-Catalyzed Alkyne-Azide Cycloaddition to Bifunctional Chelators of Interest

Applying Molecular Modeling to the Design of Innovative, Non-Symmetrical CXCR4 Inhibitors with Potent Anticancer Activity

AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor

Design, Synthesis, and Evaluation of Novel CXCR4 Antagonists Based on an Aminoquinoline Template.

Rigid Macrocycle Metal Complexes as CXCR4 Chemokine Receptor Antagonists: Influence of Ring Size

Design, Synthesis, and Biological Characterization of a New Class of Symmetrical Polyamine-Based Small Molecule CXCR4 Antagonists.

Enantioselective [4 + 2] Cycloaddition/Cyclization Cascade Reaction and Total Synthesis of cis -Bis(cyclotryptamine) Alkaloids

Selective P450<sub>BM3</sub> Hydroxylation of Cyclobutylamine and Bicyclo[1.1.1]pentylamine Derivatives: Underpinning Synthetic Chemistry for Drug Discovery

Design and synthesis of a series of pyrido[2,3-d]pyrimidine derivatives as CCR4 antagonists.

Catalytic Enantioselective Macrocyclization for the Synthesis of Planar‐Chiral Cyclophanes: Recent Updates

Mechanistic Study on Gold-Catalyzed Cycloisomerization of Dienediynes Involving Aliphatic C-H Functionalization and Inspiration for Developing a New Strategy to Access Polycarbocycles

Sidechain structure-activity relationships of cyclobutane-based small molecule αvβ3 antagonists

Computational Analysis of the Structural Mechanism of Inhibition of Chemokine Receptor CXCR4 by Small Molecule Antagonists

Design and Synthesis of Tri‐substituted Chiral Pyrrolidin‐2‐one Derivatives As CCR4 Antagonists

Synthesis of chamaecypanone C analogues from in situ-generated cyclopentadienones and their biological evaluation.